



Washington Township Health Care District

2000 Mowry Avenue, Fremont, California 94538-1716 | 510.797.1111

Kimberly Hartz, Chief Executive Officer

Board of Directors

Jacob Eapen, MD
William F. Nicholson, MD
Bernard Stewart, DDS
Michael J. Wallace
Jeannie Yee

BOARD OF DIRECTORS' MEETING
Wednesday, January 25, 2023 – 6:00 P.M.
Meeting Conducted by Teleconference
Dial In: 510-818-5900 Access Code: 6736

AGENDA

PRESENTED BY:

- | | |
|--|---|
| I. CALL TO ORDER & PLEDGE OF ALLEGIANCE | Bernard Stewart
Board President |
| II. ROLL CALL | Dee Antonio
District Clerk |
| III. COMMUNICATIONS | |
| A. Oral
<i>This opportunity is provided for persons in the audience to make a brief statement, not to exceed three (3) minutes on issues or concerns not covered by the agenda. "Request to Speak" cards should be filled out in advance and presented to the District Clerk. For the record, please state your name.</i> | |
| B. Written | |
| IV. CONSENT CALENDAR
<i>Items listed under the Consent Calendar include reviewed reports and recommendations and are acted upon by one motion of the Board. Any Board Member or member of the public may remove an item for discussion before a motion is made.</i> | Bernard Stewart
Board President |
| A. Consideration of Anesthesia Machines | <i>Motion Required</i> |
| B. Consideration of Mayfield Triad Skull Clamps | |
| C. Consideration of Thunderbolt Analyzer | |
| V. ANNOUNCEMENTS | |
| VI. CLOSED SESSION | Kimberly Hartz
Chief Executive Officer |
| A. Action Item: Consideration of Closed Session Minutes: December 14, and 19, 2022 | |

Board Meeting Agenda
January 25, 2023

- B. Report of Medical Staff and Quality Assurance Committee, Health & Safety Code section 32155
 - Medical Staff Committee Report
- C. Conference involving Trade Secrets pursuant to Health & Safety Code section 32106
 - Strategic Planning Discussion
- D. Conference with Legal Counsel – Anticipated Litigation pursuant to Government Code section 54956.9(d)(2)
 - Annual Claims Data Update

VII. OPEN SESSION

Report on Permissible Actions Taken During Closed Session

Bernard Stewart
Board President

VIII. ADJOURNMENT

Bernard Stewart
Board President

In compliance with the Americans with Disabilities Act, if you need assistance to participate in this meeting, please contact the District Clerk at (510) 818-6500. Notification two working days prior to the meeting will enable the District to make reasonable arrangements to ensure accessibility to this meeting.



Memorandum

DATE: January 18, 2023

TO: Kimberly Hartz
Chief Executive Officer

FROM: Nicholas Legge
Chief of System Operations and Support

SUBJECT: Capital Purchase – Anesthesia Machines

Anesthesia machines are critical equipment in performing surgical procedures in any operating room. They accurately mix anesthetic gases and vapors, enable patient ventilation and minimize anesthesia related risks. Most of our current machines were purchased in 2001 and are no longer supported by the vendor. With the planned future implementation of the anesthesia EPIC module and the lack of support for our current equipment, we are requesting to purchase twelve new anesthesia machines.

We worked closely with Anesthesiology, IS and the Biomedical Engineering team to evaluate machines from three different vendors. We conducted trials of each piece of equipment for one to two weeks. We decided to request the purchase of the GE Healthcare AISYS CS2 with ECOFLOW. These machines are current state of the art technology and are the only option that will interface directly with our EPIC Electronic Medical Record (EMR). Other systems require middleware in order to connect to EPIC.

The approved FY 2023 Capital Budget includes \$1,060,156.58 for this purchase. The total cost to purchase the twelve machines is \$982,367.95.

It is requested that the Board of Directors authorize the Chief Executive Officer to proceed with the necessary agreements to purchase twelve anesthesia machines from GE Healthcare in an amount not to exceed \$982,367.95.



Memorandum

DATE: January 18, 2023

TO: Kimberly Hartz
Chief Executive Officer

FROM: Nicholas M. Legge
Chief of System Operations and Support

SUBJECT: Capital Purchase – Mayfield Triad Skull Clamps

The Mayfield Triad skull clamp offers 3-point skeletal fixation, holding the head and neck in specific positions. It is often utilized in our neurosurgery cases for cranial and cervical procedures. The hospital currently owns two Mayfield Triad skull clamps made by Integra LifeSciences. Per the manufacturer, the lifespan of this equipment is seven years. We purchased our current skull clamps in 2004, which means they have been in service for eighteen years. Upon inspection, we discovered some issues that cannot be repaired. This has necessitated the renting of suitable skull clamps until replacements can be purchased.

The total cost to purchase two sets of the Mayfield Triad skull clamps is \$35,384.94. This item is not included in the FY 2023 Capital Budget; however there is currently \$25,000 available in the Washington Hospital Healthcare Foundation to support Surgical Services. We would like to utilize these funds and will make up the difference by utilizing remaining capital budget funds that are left over from other purchases.

It is requested that the Board of Directors authorize the Chief Executive Officer to proceed with the purchase of the Mayfield Triad skull clamps by Integra LifeSciences in an amount not to exceed \$35,384.94, of which \$25,000 of the expense will be covered by the Washington Hospital Healthcare Foundation.



Memorandum

DATE: January 10, 2023

TO: Washington Township Health Care District Board of Directors

FROM: Kimberly Hartz, Chief Executive Officer

SUBJECT: Request for Purchase and Install of ThunderBolt Analyzer by Qiagen

We have been working with Cardinal Health to purchase the ThunderBolt Analyzer for the Lab. ThunderBolt is a single compact walkaway fully automated analyzer. The testing library contains over 200 Enzyme Linked Immunoassay and Chemiluminescence assays including Quantiferon for the detection of Mycobacteria Tuberculosis. Quantiferon is a standardized test for the presence of Tuberculosis (TB). Testing only requires a single patient visit and can replace TB skin testing. The initial goal is to insource Quantiferon testing from ARUP. Employee Health will then only require a single visit from the employee. In addition to Quantiferon, the laboratory will be able to insource other high volume tests such as Anti-Nuclear Antibody (ANA) testing further decreasing our send out cost.

The purchase of the ThunderBolt results in a positive net income per test after expenses and average reimbursement from payors in addition to decreasing our send out testing cost.

We are recommending moving forward with this purchase in the amount of \$48,897.50. This item is included in the approved capital budget for Fiscal Year 2023.

The cost of the new equipment, which is in line with MD Buyline, is:

ITEM	COST
Thunderbolt (Equipment)	\$ 39,000.00
Tax	\$ 3,997.50
Freight	<u>\$ 5,900.00</u>
Total Capital Expense	\$ 48,897.50

It is requested that the Board of Directors authorize the Chief Executive Officer to proceed with entering into necessary agreements to move forward with the purchase of the Thunderbolt Analyzer in an amount not to exceed \$48,897.50.